All In Biotech

Drug Trial Radar · NCT03398135

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis

Last checked: Nov 20, 2026Latest source record: Jan 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,242 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,242

Actual

Start

Aug 28, 2018

Primary completion

Sep 2028

Study completion Feb 2029

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Jan 12, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who responded to induction treatment with risankizumab in a prior AbbVie study of risankizumab in UC. This study consists of three sub-studies and a Continuous Treatment Extension (CTE): Substudy 1 is a 52-week, randomized, double-blind, placebo-controlled maintenance study; Substudy 2 is 52-week, randomized, exploratory maintenance study; and Substudy 3 is an open-label long-term extension study for participants who completed Substudy 1 or 2, or participants who responded to induction treatment in Study M16-067 with no final endoscopy due to the Covid-19 pandemic or due to the geopolitical conflict in Ukraine and surrounding impacted regions. The CTE is an open-label extension for Substudy 3 completers to ensure continuous treatment with risankizumab until such time that risankizumab becomes commercially available and/or the subject can access treatment locally.

Conditions

  • Ulcerative Colitis (UC)

Interventions

  • risankizumabDrug

    subcutaneous (SC) injection

  • placebo for risankizumabDrug

    subcutaneous (SC) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sub-Study 1: Percentage of Participants Achieving Clinical Remission per Adapted Mayo ScoreTime frame: Week 52
  2. Percentage of Participants with Adverse Events (AE)Time frame: Up to Week 300

Locations

426 sites in 43 countries. Site status is shown where the registry gives one.

  • Southern California Res. Ctr. /ID# 169659

    Coronado, California

  • Hoag Memorial Hosp Presbyterian /ID# 218347

    Irvine, California

  • UC San Diego Health System /ID# 160430

    La Jolla, California

  • United Medical Doctors /ID# 158574

    Los Alamitos, California

  • Cedars-Sinai Medical Center /ID# 163848

    Los Angeles, California

  • Gastrointestinal Biosciences Clinical Trials, LLC /ID# 200934

    Los Angeles, California

  • UCSF Medical Center - Mount Zion /ID# 201209

    San Francisco, California

  • Peak Gastroenterology Associates, PC /ID# 165838

    Colorado Springs, Colorado

  • Rocky Mountain Pediatric Gastroenterology /ID# 207173

    Lone Tree, Colorado

  • Duplicate_Medical Research Center of CT /ID# 160287

    Hamden, Connecticut

  • Yale Univ Digestive Diseases /ID# 213265

    New Haven, Connecticut

  • South Lake Pain Institute, Inc /ID# 162859

    Clermont, Florida

  • Ctr for Advanced Gastroenterol /ID# 202820

    Maitland, Florida

  • University of Miami /ID# 160456

    Miami, Florida

  • Coral Research Clinic /ID# 158608

    Miami, Florida

  • South Florida Research Ph I-IV, Inc. /ID# 161844

    Miami, Florida

  • Gastroenterology Group Naples /ID# 165210

    Naples, Florida

  • Advanced Research Institute, Inc /ID# 161945

    New Port Richey, Florida

  • Advent Health /ID# 160393

    Orlando, Florida

  • Endoscopic Research, Inc. /ID# 206709

    Orlando, Florida

  • Omega Research Group /ID# 203105

    Orlando, Florida

  • Duplicate_Lenus Research & Medical Group /ID# 169727

    Sweetwater, Florida

  • Clinical Research Trials of Florida, Inc. /ID# 201794

    Tampa, Florida

  • Duplicate_AdventHealth Tampa /ID# 170482

    Tampa, Florida

  • Gastroenterology Associates of Central Georgia, LLC /ID# 160513

    Macon, Georgia

  • The University of Chicago Medical Center /ID# 160511

    Chicago, Illinois

  • DM Clinical Research/Southwest /ID# 165009

    Oak Lawn, Illinois

  • Indiana University /ID# 167250

    Indianapolis, Indiana

  • Univ Kansas Med Ctr /ID# 226601

    Kansas City, Kansas

  • Cotton O'Neil Clinical Research Center, Digestive Health /ID# 160367

    Topeka, Kansas

  • Duplicate_Robley Rex VA Medical Center /ID# 218647

    Louisville, Kentucky

  • Houma Digestive Health Special /ID# 158377

    Houma, Louisiana

  • Delricht Research /ID# 206817

    New Orleans, Louisiana

  • Nola Research Works, LLC /ID# 161356

    New Orleans, Louisiana

  • Louisiana Research Center, LLC /ID# 201205

    Shreveport, Louisiana

  • Massachusetts General Hospital - Crohn's and Colitis Center /ID# 164257

    Boston, Massachusetts

  • University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 159430

    Ann Arbor, Michigan

  • Clin Res Inst of Michigan, LLC /ID# 160300

    Chesterfield, Michigan

  • Mayo Clinic - Rochester /ID# 200455

    Rochester, Minnesota

  • Quality Clinical Research Inc. /ID# 167312

    Omaha, Nebraska

Showing 40 of 426 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.